Respiratory syncytial virus vaccination;Vaccination anti-virus respiratoire syncytial

Virologie

Volumn 7, Issue SPEC. ISS. OCT., 2003, Pages

  Gaudelus, J ^a  

^a HÔPITAL JEAN VERDIER   (France)

Author keywords

Bronchiolitis; RSV; RSV vaccination; Vaccinal strategy

Indexed keywords

ALUMINUM HYDROXIDE; DNA VACCINE; HYBRID PROTEIN; INACTIVATED VACCINE; PROTEIN SUBUNIT; PURIFIED F PROTEIN; PURIFIED FUSION PROTEIN; RECOMBINANT INTERLEUKIN 12; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

BRONCHIOLITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; PRESCHOOL CHILD; PROTEIN PURIFICATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; TREATMENT INDICATION; VACCINATION; VIRUS INFECTION;

PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 0242612036     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Thelot R, Benichou JJ, Cheron G, et al. Surveillance épidé miologiqae hospitalière de la bronchiolite du nourrisson par le réseau Erbus. Rev Epidemiol Santé Publ 1998; 46: 277-88.
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis associated hospitalizations among US children 1980-1996. JAMA 1999; 282: 1440-6.
3. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344: 1917-28.
4. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 1436-42.
5. Selwyn BJ and the Coordinated Data Group of Bostid Researchers, The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Rev Infect Dis 1990; 12 (suppl. 8): S870-8.
6. Weltzin R, Traina-Dorge V, Soike K, et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis 1996; 174: 256-61.
7. Piedra PA. Future directions in vaccine prevention of respiratory syncythial virus. Pediatr Infect Dis J 2002; 21: 482-7.
8. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infections: immune response, immunopathogenesis and treatment. Clin Microbiol Rev 1999; 12: 298-309.
9. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980; 96: 179-86.
10. Hall CB, Powell KR, McDonald NE. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986; 315: 77-81.
11. Graham BS, Henderson GS, Tang YW, et al. Priming immunization determines T helper cytokine in RNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151: 2032-40.
12. Murphy BR, Alling DW, Synder MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986; 24: 894-8.
13. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J Pediatr 1981; 98: 708-15.
14. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422-34.
15. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998; 11: 430-9.
16. Karron RA, Steinhoff MC, Subbarao EK, et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995; 14: 10-6.
17. Crowe JE, Firestone CY, Br M. Passively acquired antibodies suppress humoral but not cell mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001; 167: 3910-8.
18. Crowe JE, Bui PH, Siber GR, Elinks WR, Chanock RM, Murphy BR. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995; 13: 847-55.
19. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182: 1331-42.
20. Karron RA, Wright PF, Crowe JE, et al. Evaluation of two live, cold passaged, temperature sensitive respiratory syncytial virus vaccines in chimpanzees and human adults, infants and children. J Infect Dis 1997; 176: 1428-36.
21. Hancock GE, Smith JD, Heers KM. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachement proteins of respiratory syncytial virus. J Infect Dis 2000; 181: 1768-71.
22. Gonzalez IM, Karron RH, Eichelberger M, et al. Evaluation of the live attenuated cpts 248-404 RSV vaccine in combination with a subunit RSV vaccine (PFP2) in healthy young and older adults. Vaccine 2000; 18: 1763-72.
23. Whitehead SS, Hill MG, Firestone CY, et al. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol 1999; 73: 9773-80.
24. Walsh EE. Humoral, mucosal and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. J Infect Dis 1994; 170: 345-50.
25. Tebbey PW, Schever CA, Peek JA, et al. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 2000; 18: 2723-34.
26. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993; 167: 191-5.
27. Paradiso PR, Hildreth SW, Hogerman DA, et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994; 13: 792-8.
28. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996; 15: 23-31.
29. Piedra PA, Grace S, Jewell A, et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 1998; 17: 217-24.
30. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EAF. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998; 177: 467-9.
31. Englund JA, Glezen WP, Piedra PA. Maternal immunization against viral disease. Vaccine 1998; 16: 1456-63.
32. Munoz FM, Piedra PA, Maccatto M, Kozinetz C, Glezen PW. Respiratory syncytial virus purified fusion protein 2 (PFP2) vaccine in pregnancy. In: RSV after 45 years from bedside to bunch. Segovia, Spain, October 1 to 3 2001 [1] abst. 158.
33. Brandt CD, Power UF, Plotnicky-Gilquin H, et al. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis 1997; 176: 884-91.
34. 2Na. Vaccine 2000; 18: 2648-55.
35. Wathen MW, Kakuk TJ, Bridaeu RJ, Hausknecht EC, Cole SL, Zaya RM. Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis 1991; 163: 477-82.
36. Hancock GE, Smith JO, Heers KM. The immunogenicity of subunit vaccines for respiratory syncytial virus after coformulation with aluminium hydroxide adjuvant and recombinant interleukin 12. Viral Immunol 2000; 13: 57-72.
37. Li X, Sambhara S, Li CX, et al. Protection against respiratory syncytial virus infection by ADN immunization. J Exp Med 1998; 188: 681-8.
38. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 2000; 81: 2519-23.
39. Hsu KHL, Lubeck MD, Davis AR, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5 and 7 vectors in dogs and a chimpanzee. J Infect Dis 1992; 166: 769-75.
40. Collins PL, Purcell RH, Londen WT, Lawrence LA, Chanock RM, Murphy BR. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 1990; 8: 164-8.
41. Kneyber MCJ, Kimpen JLL. Current concepts on active immunization against respiratory syncytial virus for infants and young children. Pediatr Infect Dis J 2002; 21: 685-96.